Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Esmann, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Esmann, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 17-27
© 2001 The British Society for Antimicrobial Chemotherapy

The many challenges of facial herpes simplex virus infection

Jørgen Esmann,*

Centre for Laser Surgery, Ryvangsallé 54, 2900 Hellerup, Denmark

Infection with herpes simplex virus type 1 (HSV-1) is common throughout the world, with many cases leading to symptomatic facial herpes. Following primary infection, HSV-1 establishes chronic latency, usually in the trigeminal ganglia, from where it reactivates periodically to cause recurrent outbreaks of infection. Recurrent facial herpes episodes vary in severity; they may be asymptomatic or appear as maculo-papular lesions that subsequently regress (abort), or vesicular lesions may develop which then scab prior to healing. Symptomatic lesions usually occur on the lips, cheeks, within the nose or on the nasal septum; they are often painful and unsightly. During asymptomatic or symptomatic outbreaks, HSV-1 is shed and thus there is a risk of transmission to susceptible individuals. Antiviral therapy in oral or topical formulations has been shown to be effective in treating facial herpes outbreaks. Oral therapy may also be used to suppress frequently recurring or severe episodes. For lesions at less readily accessible sites or when the risk of autoinoculation is high, oral therapy is warranted.

1 *Tel: +45-39-458-700; E-mail: je{at}lkk.dk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
cfpHome page
W. Opstelten, A. K. Neven, and J. Eekhof
Treatment and prevention of herpes labialis
Can Fam Physician, December 1, 2008; 54(12): 1683 - 1687.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.